Non-traumatic hip pain in adolescents presents a significant diagnostic challenge. We report the case of a 19-year-old female patient treated for idiopathic juvenile osteoporosis with zoledronic acid, presenting with chronic inflammatory right hip pain that responded well to NSAIDs, associated with back and buttock pain. The inflammatory markers, including CRP and ESR, were negative. The pelvic radiography was normal, though thoracolumbar spine radiography revealed scoliosis. Consequently, MRI of the sacroiliac joints was performed to search for sacroiliitis but revealed a 5 mm nidus with reactive sclerosis, suggestive of an osteoid osteoma. The natural progression of the patient's pain showed spontaneous regression within one year.

**Keywords:** Osteoid Osteoma, Case Report, Femoral Neck, Bisphosphonate, Nidus.

**INTRODUCTION**

Hip pain in children and adolescents presents a diagnostic challenge of varying difficulty, sometimes with rare but treatable causes requiring rigorous diagnostic management. We report the case of an adolescent patient presenting with chronic back pain, buttock pain, and inflammatory right hip pain, where investigations revealed a rare osteoid osteoma.

**CASE REPORT**

We report the case of J.E., a 19-year-old asthmatic female on inhaled corticosteroids, followed for idiopathic juvenile osteoporosis since 2019, treated with four cycles of zoledronic acid, showing good clinical and densitometric improvement.

The patient was followed for chronic back pain, with standard radiography revealing thoracolumbar scoliosis, diagnosed as idiopathic scoliosis. One year ago, she presented with the onset of inflammatory right buttock pain, exacerbation of her low back pain, and inflammatory right hip pain responsive to NSAIDs. Clinical examination noted pain with sacroiliac maneuvers without spinal syndrome or hip joint limitation.

The inflammatory markers, including CRP and ESR, were negative and pelvic radiography showed no abnormalities. Hip ultrasound revealed a minimal effusion in the right coxofemoral (CF) joint. Given the patient's clinical presentation and history, chronic inflammatory rheumatic disease such as spondyloarthritis was first considered. Pelvic MRI to assess the SI joints and CF joint showed no signs of inflammatory sacroiliitis but revealed a condensation image in the anterior femoral neck, suggestive of an osteoid osteoma (OO) with a 5 mm nidus (Figures 1a and 1b). Surgical indication for radiofrequency ablation was made, but the natural progression in our patient showed spontaneous pain regression after one year.
**DISCUSSION**

Osteoid osteoma (OO) was first reported by Jaffe in 1935 in a series of five cases [1]. It is a benign osteogenic tumor characterized by persistent pain, worsening at night, and relieved by NSAIDs and salicylates [2, 3]. It is particularly common in adolescents and young adult males; moreover, 50% of these tumors occur in the second decade of life, being rare before age 5 and after age 35[4].

Positive diagnosis relies on clinical and imaging findings, detecting the typical OO nidus, generally small, measuring up to 1-2 cm, usually surrounded by cortical periosteal thickening [4, 5]. Edeiken's radiographic classification categorizes OO as cortical, medullary, or subperiosteal [4]. Histologically, the nidus comprises an osteoid matrix and trabecular bone surrounded by active osteoblasts, osteoclasts, and vascular structures. The sclerosis surrounding the lesion is a reaction to pressure caused by the highly vascularized nidus, which may be absent or minimal in intra-articular lesions [6].

OO is often located in the diaphysis and metaphysis of long bones, with the femur and tibia affected in over 50% of cases [4]. Femoral neck OO is notable, but due to its proximity to the hip joint, clinical manifestations can be misleading [7], increasing diagnostic error likelihood, with a delay of up to 14 months from symptom onset to diagnosis [3].

A study by Hao Zeng et al. reported 35 patients with proximal femur OO, with 15 patients (42.9%) initially misdiagnosed with conditions such as synovitis, Perthes disease, osteomyelitis, intra-articular infection, joint tuberculosis, and hip impingement syndrome, with an average delay of 6.3 months from symptom onset to diagnosis [3].

Natural progression may include spontaneous regression over 6-15 years, though NSAIDs use can reduce this period to 2-3 years [4]. Curative treatment primarily involves surgical intervention with complete tumor excision, leading to healing and an exceptional recurrence risk [11]. Biopsy is recommended for percutaneous treatment, especially for atypical lesions, though it may not be diagnostic in about one-third of cases [4, 12].

OO treatment of the femur varies based on anatomical location, local expertise, and available resources [13]. Femoral OO can be treated medically with NSAIDs or salicylates [14]. However, interventional treatments offer definitive cure and overcome long-term NSAID and salicylate side effects. Traditionally, surgical resection, curettage, and scraping of the OO nidus have been described. New minimally invasive techniques with less morbidity and faster recovery include CT-guided percutaneous radiofrequency ablation, thermal destruction, laser ablation, CT-guided percutaneous drilling, and arthroscopic nidus removal [14].

All minimally invasive treatment options have yielded satisfactory results, exceeding 90% success rates, with CT-guided radiofrequency and arthroscopy being potentially the most effective options [13].

Alternative therapeutic options for inaccessible OOs include bisphosphonates, particularly zoledronic acid, which can inhibit in vitro prostaglandin E2 (PGE2) synthesis by osteoblasts, known to increase in OOs.
Besides their anti-prostaglandin effect, bisphosphonates demonstrate anti-angiogenic properties, affecting endothelial and stromal vascular cell proliferation, adhesion, and migration within the lesion [15].

A study involving three patients treated with monthly zoledronic acid for 3-6 months showed efficacy, with OO regression and no recurrence over a 5-year follow-up [15]. In our case, pain reduction might be due to the natural evolution of the OO or zoledronic acid administration for juvenile osteoporosis in our patient.

**CONCLUSION**

OO is a benign tumor that can sometimes be confused with chronic inflammatory rheumatism. Today, diagnosis is facilitated by advances in medical imaging. Minimally invasive and non-invasive approaches offer increased efficacy with better tolerance. While bisphosphonates’ efficacy is not fully demonstrated, future studies with larger samples are desirable.

**REFERENCE**